ABC | Volume 113, Nº5, November 2019

Review Article Fernandes et al. Deposit diseases and ventricular hypertrophy Arq Bras Cardiol. 2019; 113(5):979-987 1. Pereira NL, Grogan M, Dec GW. Spectrum of restrictive and infiltrative cardiomyopathies: Part 1 of a 2-Part Series. J Am Coll Cardiol. 2018;71(10):1130-48. 2. Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014;129(18):1840-9. 3. Kristen AV, Maurer MS, Rapezzi C, Mundayat R, Suhr OB, Damy T, et al. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS). PLoS One. 2017;12(4):e0173086. 4. Gutierrez PS, Fernandes F, Mady C, Higuchi Mde L .Clinical, electrocardiographic and echocardiographic findings in significant cardiac amyloidosis detected only at necropsy: comparison with cases diagnosed in life. Arq Bras Cardiol. 2008;90(3):191-6. 5. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chainmeasurements. J ClinOncol. 2012;30(9):989-95. 6. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357-77. 7. Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T , Ando Y . Diagnosis and managementoftransthyretinfamilialamyloidpolyneuropathyinJapan:red-flag symptomclustersandtreatmentalgorithm. OrphanetJRareDis.2 018;13(1):6. 8. GertzMA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer J. 2018;8(5):44. 9. González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro- Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585-94. 10. Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM , et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2(2):113-22. 11. MaurerMS, HannaM, GroganM, Dispenzieri A,Witteles R, Drachman B, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey); THAOS Investigators. J Am Coll Cardiol. 2016;68(2):161-72. 12. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses:diseaseprofilesandclinicalcourses of the 3maintypes. Circulation. 2009;120(13):1203-12. 13. Nietlispach F, Webb JG, Ye J, Cheung A, Lichtenstein SV, Carere RG, et al. Pathology of transcatheter valve therapy. JACC Cardiovasc Interv. 2012;5(5):582–90. 14. Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging. 2016;9(8). pii: e005066. 15. Lamke GT, Allen RD, Edwards WD, Tazelaar HD, Danielson GK. Surgical pathology of subaortic septal myectomy associated with hypertrophic cardiomyopathy. A study of 204 cases (1996-2000). Cardiovasc Pathol. 2003;12(3):149–58. 16. Helder MR, Schaff HV, Nishimura RA, Gersh BJ, Dearani JA, Ommen SR, et al. Impact of incidental amyloidosis on the prognosis of patients with hypertrophic cardiomyopathy undergoing septal myectomy for left ventricular outflow tract obstruction. Am J Cardiol. 2014;114(9):1396–9. 17. Damy T, Costes B, Hagège AA, Donal E, Eicher JC, SlamaM, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37(23):1826-34. 18. Phelan D , Collier P , Thavendiranathan P , Popović ZB , Hanna M , Plana JC, et al. R elative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442-8. 19. Fontana M, Pica S, Reant P , Abdel-Gadir A, Treibel TA, Banypersad SM. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570-9. 20. Clesham GJ, Vigushin DM, Hawkins PN, Pepys MB, Oakley CM, Nihoyannopoulos P. Echocardiographic assessment of cardiac involvement in systemic AL amyloidosis in relation to whole body amyloid load measured by serumamyloidPcomponent(SAP)clearance.AmJCardiol.1997;80(8):1104-8. 21. HongoM, IkedaS.Echocardiographicassessmentoftheevolutionofamyloid heart disease: a study with familial amyloid polyneuropathy. Circulation. 1986;73(2):249-56. 22. Mesquita ET, Jorge AJL, Souza CV Junior, Andrade TR. Cardiac amyloidosis and its newclinical phenotype: heart failurewith preserved ejection fraction. Arq Bras Cardiol. 2017;109(1):71-8. 23. AppletonCP,HatleLK,PoppRL.Relationoftransmitralflowvelocitypatternsto leftventriculardiastolicfunction:newinsightsfromacombinedhemodynamic andDoppler echocardiographic study. J AmColl Cardiol. 1988;12(2):426-40. 24. Appleton CP, Hatle LK, Popp RL. Demonstration of restrictive ventricular physiology by Doppler echocardiography. J Am Coll Cardiol. 1988;11(4):757-68. 25. Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol. 2009;103(3):411-5. References Author contributions Conception and design of the research andAcquisition of data: Fernandes F, Antunes MO; Analysis and interpretation of the data and Writing of the manuscript: Fernandes F, Antunes MO, Hotta VT, Rochitte CE; Critical revision of the manuscript for intellectual content: Fernandes F, AntunesMO,HottaVT, RochitteCE,MadyC. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding There were no external funding sources for this study. Study Association This study is not associatedwith any thesis or dissertationwork. Ethics approval and consent to participate This article does not contain any studies with human participants or animals performed by any of the authors. 985